| human | Q5 |
| P6178 | Dimensions author ID | 0746030444.54 |
| P8446 | Gateway to Research person ID | C6EEB798-B17D-4B9A-A820-1657D3695D7B |
| P496 | ORCID iD | 0000-0002-1435-2942 |
| P1153 | Scopus author ID | 35743356800 |
| P108 | employer | Queen's University Belfast | Q877925 |
| P734 | family name | Laverty | Q37496538 |
| Laverty | Q37496538 | ||
| Laverty | Q37496538 | ||
| P735 | given name | Garry | Q19801888 |
| Garry | Q19801888 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q35756676 | Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens |
| Q40229905 | Antibiotic susceptibility of planktonic- and biofilm-grown staphylococci isolated from implant-associated infections: should MBEC and nature of biofilm formation replace MIC? |
| Q33550548 | Antimicrobial activity of short, synthetic cationic lipopeptides. |
| Q41456988 | Antimicrobial efficacy of an innovative emulsion of medium chain triglycerides against canine and feline periodontopathogens |
| Q83844550 | Antimicrobial peptide incorporated poly(2-hydroxyethyl methacrylate) hydrogels for the prevention of Staphylococcus epidermidis-associated biomaterial infections |
| Q41723689 | Biofilm eradication kinetics of the ultrashort lipopeptide C12 -OOWW-NH2 utilizing a modified MBEC Assay(™). |
| Q38273317 | Biomolecular Mechanisms of Pseudomonas aeruginosa and Escherichia coli Biofilm Formation. |
| Q38093647 | Biomolecular mechanisms of staphylococcal biofilm formation. |
| Q41197924 | Developing Entrepreneurial Skills in Pharmacy Students. |
| Q90346396 | Development of a teaching model to advance skills in industrial pharmaceutical formulation and regulatory aspects |
| Q33455715 | Eradication of Pseudomonas aeruginosa biofilms by atmospheric pressure non-thermal plasma |
| Q34809662 | Evolution of antimicrobial peptides to self-assembled peptides for biomaterial applications |
| Q33468060 | Non-thermal Plasma Exposure Rapidly Attenuates Bacterial AHL-Dependent Quorum Sensing and Virulence |
| Q38955620 | Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients. |
| Q47803998 | Peptide nanomaterials as future antimicrobial technologies |
| Q96134469 | Pharmaceutical Formulation and Characterization of Dipeptide Nanotubes for Drug Delivery Applications |
| Q38847017 | Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections. |
| Q90380933 | Self-assembling diphenylalanine peptide nanotubes selectively eradicate bacterial biofilm infection |
| Q37954604 | The potential of antimicrobial peptides as biocides |
| Q53207774 | The use of water-soluble mucoadhesive gels for the intravesical delivery of epirubicin to the bladder for the treatment of non-muscle-invasive bladder cancer. |
| Q97638252 | Tuning the antimicrobial activity of low molecular weight hydrogels using dopamine autoxidation |
| Q91186744 | Ultrashort Self-Assembling Peptide Hydrogel for the Treatment of Fungal Infections |
| Q38971138 | Ultrashort cationic naphthalene-derived self-assembled peptides as antimicrobial nanomaterials. |
| Q40380058 | Ultrashort self-assembling Fmoc-peptide gelators for anti-infective biomaterial applications |
| Q38910206 | Using debate to teach pharmacy students about ethical issues |
Search more.